IB Acquisition Corp. (IBAC): Cash & Equivalents
$428.7K
As of 2025-09-30
$30.2K
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $428.7K | -47.9% | 2025-12-29, Balance as of period end |
| 2024-09-30 | $822.8K | n/m | 2025-12-29, Balance as of period end |
| 2023-09-30 | $52.6K | n/a | 2024-12-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| IB Acquisition Corp. (IBAC) | 2025-09-30 | $428.7K | -47.9% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $6.45M | +483.5% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.88M | +266.3% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $207.5K | +203.9% |
| NRC Health (NRC) | 2025-12-31 | $4.14M | -2.2% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $585.0K | +240.1% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $20.07M | -28.0% |
| Absci Corp (ABSI) | 2025-12-31 | $20.02M | -51.4% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $25.52M | -7.5% |
Compare IBAC, BIAF, ISPC, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗